Clinical trials: Extensive Disease Small Cell Lung Cancer
SCLC, Extensive Stage
Anti-PD-1 and VEGF Bispecific Antibody AK112 in Combination With Chemotherapy in Patients With ES-SCLC
Phase Ib open label, multicenter study to evaluate the efficacy and safety of anti-PD-1 and VEGF bispecific antibody (AK112) combined with chemotherapy in patients with ES-SCLC.
- Trial name
- NCT05116007
- Testing
- AK112, Etoposide, Carboplatin
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Akeso
Small-cell Lung Cancer
Liver Directed RT + Chemo-immunotherapy for ES-SCLC
The purpose of this study is to evaluate whether radiation treatment directed at liver metastases can be safely added to standard of care treatment for extensive stage small cell lung cancer (ES-SCLC).
- Trial name
- NCT04923776
- Testing
- Carboplatin, Etoposide, Atezolizumab
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Brian Henick, MD
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Phase 1 Study of HS-20093 Combinations in Patients With Extensive Stage Small Cell Lung Cancer
This is a Phase I clinical study of HS-20093. The purpose of this study is to evaluate the safety, tolerability, PK and efficacy of HS-20093 in combination with Adebrelimab in patients with Extensive Stage Small Cell Lung Cancer…
- Trial name
- NCT07063407
- Testing
- HS-20093 in combination with Adebrelimab
- Volunteers
- 50 people
- Sponsor
- Shanghai Hansoh Biomedical Co., Ltd
Extensive Stage Lung Small Cell Carcinoma
Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer
This phase II trial tests the effect of tarlatamab in treating patients with small-cell lung cancer (SCLC) that has spread from where it first started to other parts of the body (extensive-stage).
- Trial name
- NCT07423585
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Asrar Alahmadi
Extensive-Stage Small Cell Lung Cancer
Efficacy and Safety of IBI308 and Paclitaxel/Albumin Paclitaxel for SCLC Patients Who Failed Etoposide Chemotherapy
This phase II trial studies how well IBI308 combined with paclitaxel/albumin-bound paclitaxel work in treating participants with small cell lung cancer after failing to platinum-etoposide chemotherapy.
- Trial name
- NCT04056949
- Testing
- Paclitaxel/Albumin-Bound Paclitaxel, IBI308
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Junling Li
SCLC, Extensive Stage
Utidelone in Third-line and Above Treatment of Small Cell Lung Cancer
SCLC has a very high degree of malignancy, and 60% to 70% of patients are diagnosed as extensive stage. The median survival of patients with limited-stage disease is about 15-20 months, and the median OS of patients with…
- Trial name
- NCT05299255
- Testing
- Utidelone
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Henan Cancer Hospital
Platinum-Resistant Lung Small Cell Carcinoma, Platinum-Sensitive Lung Small Cell Carcinoma
Durvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung Cancer
This phase II trial studies the effects of durvalumab and lurbinectedin in treating patients with extensive stage small cell lung cancer that has come back (relapsed) or has not responded to previous treatment with chemotherapy…
- Conditions
- Platinum-Resistant Lung Small Cell Carcinoma, Platinum-Sensitive Lung Small Cell Carcinoma, Recurrent Extensive Stage Lung Small Cell Carcinoma, Refractory Extensive Stage Lung Small Cell Carcinoma
- Trial name
- NCT04607954
- Testing
- Durvalumab, Lurbinectedin
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Mayo Clinic
Carcinoma, Small Cell
Study of Pemetrexed and Gemcitabine for Patients With a New Diagnosis of Extensive-Stage Small Cell Lung Cancer
The purpose of the study is to determine whether pemetrexed and gemcitabine cause good tumour shrinkage when given to patients with previously untreated extensive-stage small cell lung cancer.
- Trial name
- NCT00129974
- Testing
- pemetrexed and gemcitabine
- Where
- 3 sites in United States
- Volunteers
- 1 people
- Sponsor
- Tufts Medical Center
Stage IV Non-small Cell Lung Cancer, Extensive-stage Small Cell Lung Cancer
Impact of eHealth Monitoring on Overall Survival in Patients With Metastatic NSCLC / Extensive-stage SCLC / Advanced TNBC Under First-line Treatment With Atezolizumab Plus Chemotherapy
The current study is aimed to test the benefit of a web-based application tool in NSCLC, SCLC and TNBC patients during the recently approved first-line treatment strategy with atezolizumab in combination with chemotherapy.
- Conditions
- Stage IV Non-small Cell Lung Cancer, Extensive-stage Small Cell Lung Cancer, Advanced (Locally Advanced and Inoperable or Metastatic), PD-L1 IC-positive TNBC
- Trial name
- CHAPLIN (NCT03911219)
- Testing
- eHealth system support for symptom management via CANKADO
- Where
- 92 sites in Germany
- Volunteers
- 154 people
- Sponsor
- iOMEDICO AG
Extensive-stage Small Cell Lung Cancer
A Phase I/II Study of Carboplatin and Etoposide With or Without Obatoclax in Extensive-stage Small Cell Lung Cancer (ES-SCLC)
The Phase I portion of this protocol will determine the best phase II dose and schedule of obatoclax with carboplatin and etoposide in patients with extensive-stage small cell lung cancer.
- Trial name
- NCT00682981
- Testing
- Obatoclax, Carboplatin/etoposide
- Where
- 75 sites in United States, Bulgaria and 8 more
- Volunteers
- 218 people
- Sponsor
- Gemin X
SCLC, SCLC, Extensive Stage
68Ga-PFD3 PET Imaging for the Diagnosis and Evaluation of Small Cell Lung Cancer
This study aims to investigate and evaluate the safety and performance of a novel probe, PFD3, for the diagnosis and assessment of patients with small cell lung cancer (SCLC).
- Conditions
- SCLC, SCLC, Extensive Stage, SCLC, Limited Stage, Small Cell Lung Cancer
- Trial name
- NCT07508852
- Testing
- Sequential [18F]-FDG PET/CT, [68Ga]Ga-PFD3 PET/CT scan
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking University First Hospital
Extensive-stage Small-cell Lung Cancer
Phase 3 Study Evaluating Efficacy, Safety and Pharmacokinetics of Trilaciclib In Small Cell Lung Cancer Patients
A Randomized, double-blind, placebo-controlled, multi-center Phase 3 study evaluating efficacy, safety and pharmacokinetics of Trilaciclib In Extensive-Stage Small Cell Lung Cancer Patients Receiving Carboplatin combined with…
- Trial name
- NCT04902885
- Testing
- Trilaciclib, carboplatin, etoposide，or Topotecan
- Where
- China
- Volunteers
- 95 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Lung Cancer
Combination Chemotherapy in Treating Patients Who Have Extensive-Stage Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003696
- Testing
- carboplatin, cyclophosphamide, doxorubicin hydrochloride
- Where
- Netherlands
- Volunteers
- 250 people
- Sponsor
- Commissie Voor Klinisch Toegepast Onderzoek
Extensive-stage Small-cell Lung Cancer
A Study of Adebrelimab Combined With Famitinib and Chemotherapy in the Treatment of ES-SCLC.
This is a single arm, multi-center, phase II trial to evaluate the efficacy, and safety of adebrelimab combined with famitinib and chemotherapy for the treatment of first-line extensive stage small cell lung cancer.
- Trial name
- NCT06306560
- Testing
- adebrelimab, famitinib, chemotherapy
- Volunteers
- 40 people
- Sponsor
- Harbin Medical University
SCLC, Anlotinib
Anlotinib Plus Etoposide and Carboplatin as First-line Treatment for Extensive-stage Small Cell Lung Cancer
This is a phase II, open-label, single center study, aiming to investigate safety and efficacy of etoposide and carboplatin (administered intravenously) in combination with anlotinib (administered orally) in treatment-naive…
- Trial name
- NCT04684017
- Testing
- Anlotinib hydrochloride, Etoposide, Carboplatin
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Shanghai Chest Hospital
Small Cell Lung Cancer
A Study of IMGN901 for Patients With Advanced Solid Tumors and Extensive Stage Small Cell Lung Cancer
The purpose of this study is to test safety and efficacy of this combination treatment (IMGN901, carboplatin and etoposide) in patients with solid tumors and extensive stage small cell lung cancer.
- Trial name
- NCT01237678
- Testing
- IMGN901, Carboplatin and Etoposide
- Where
- 48 sites in United States, Canada and 2 more
- Volunteers
- 181 people
- Sponsor
- ImmunoGen, Inc.
Small Cell Lung Cancer
Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)
The primary objective of this study is to demonstrate non-inferiority in pharmacokinetic (PK) parameters of subcutaneous (SC) vs intravenous (IV) tarlatamab administration and to characterize the efficacy, safety, and…
- Trial name
- DeLLphi-315 (NCT07778316)
- Testing
- Tarlatamab
- Where
- 9 sites in United States, Australia and 3 more
- Volunteers
- 400 people
- Sponsor
- Amgen
Carcinoma, Small Cell Lung
Irinotecan, Carboplatin, Bevacizumab in the Treatment of Patients With Extensive Stage Small Cell Lung Cancer
This multicenter phase II trial is designed to study the unique combination of chemotherapy (irinotecan./carboplatin) and bevacizumab in the extensive-stage setting.
- Trial name
- NCT00294931
- Testing
- irinotecan, carboplatin, bevacizumab
- Where
- 4 sites in United States
- Volunteers
- 50 people
- Sponsor
- SCRI Development Innovations, LLC
Small Cell Lung Cancer
Carboplatin and Etoposide in Combination With Vorinostat for Patients With Extensive Stage Small Cell Lung Cancer
The Phase I portion of the study is to assess the maximum tolerated dose of vorinostat when combined with carboplatin plus etoposide.
- Trial name
- NCT00702962
- Testing
- Vorinostat, Carboplatin, Etoposide
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Milton S. Hershey Medical Center
SCLC, Extensive Stage
Patients With ES-SCLC and ECOG PS=2 Receiving Atezolizumab-Carboplatin-Etoposide
Small cell lung cancer (SCLC) is a rapidly proliferating, neuroendocrine tumor that accounts for about 15% of all lung cancers. Most patients have metastases at primary diagnosis involving sites like bone, adrenal glands, liver…
- Trial name
- SPACE (NCT04221529)
- Testing
- Atezolizumab
- Where
- 19 sites in Austria, Germany
- Volunteers
- 70 people
- Sponsor
- AIO-Studien-gGmbH